Pharmacokinetics of Tildipirosin in Ewes after Intravenous, Intramuscular and Subcutaneous Administration
A single-dose disposition kinetics for tildipirosin was evaluated in clinically healthy ewes (<i>n</i> = 6) after intravenous (IV), intramuscular (IM), and subcutaneous (SC) administration of a commercial formulation. Tildipirosin concentrations were determined by high-performance liquid...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-08-01
|
| Series: | Animals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-2615/10/8/1332 |
| _version_ | 1827711843674619904 |
|---|---|
| author | Juan Sebastián Galecio Elisa Escudero José Joaquín Cerón Giuseppe Crescenzo Pedro Marín |
| author_facet | Juan Sebastián Galecio Elisa Escudero José Joaquín Cerón Giuseppe Crescenzo Pedro Marín |
| author_sort | Juan Sebastián Galecio |
| collection | DOAJ |
| description | A single-dose disposition kinetics for tildipirosin was evaluated in clinically healthy ewes (<i>n</i> = 6) after intravenous (IV), intramuscular (IM), and subcutaneous (SC) administration of a commercial formulation. Tildipirosin concentrations were determined by high-performance liquid chromatography with ultraviolet detection. Plasma concentration-time data was calculated by non-compartmental pharmacokinetic methods. The apparent volume of distribution (Vz) of tildipirosin after IV administration was 5.36 ± 0.57 L/kg suggesting a wide distribution in tissues and inside the cells. The elimination half-life (t½λz) was 17.16 ± 2.25, 23.90 ± 6.99 and 43.19 ± 5.17 h after IV, IM and SC administration, respectively. Following IM administration, tildipirosin was rapidly absorbed (tmax = 0.62 ± 0.10 h) even to a greater extent than after SC administration. Time to reach peak concentration (tmax) and peak plasma concentrations (Cmax) differed significantly, but both parameters showed a more significant variability after SC than after IM administration. Bioavailabilities after extravascular administration were high (>70%). Therefore, given general adverse reactions that were not observed in any ewe and favourable pharmacokinetics, tildipirosin could be effective in treating bacterial infections in sheep. |
| first_indexed | 2024-03-10T18:02:18Z |
| format | Article |
| id | doaj.art-89c0989dbec34577a24d53108fb1c1b0 |
| institution | Directory Open Access Journal |
| issn | 2076-2615 |
| language | English |
| last_indexed | 2024-03-10T18:02:18Z |
| publishDate | 2020-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Animals |
| spelling | doaj.art-89c0989dbec34577a24d53108fb1c1b02023-11-20T08:46:04ZengMDPI AGAnimals2076-26152020-08-01108133210.3390/ani10081332Pharmacokinetics of Tildipirosin in Ewes after Intravenous, Intramuscular and Subcutaneous AdministrationJuan Sebastián Galecio0Elisa Escudero1José Joaquín Cerón2Giuseppe Crescenzo3Pedro Marín4Department of Pharmacology, Faculty of Veterinary Medicine, University of Murcia, 30100 Murcia, SpainDepartment of Pharmacology, Faculty of Veterinary Medicine, University of Murcia, 30100 Murcia, SpainInterdisciplinary Laboratory of Clinical Pathology, Interlab–UMU, University of Murcia, 30100 Murcia, SpainDepartment of Veterinary Medicine, University of Bari Aldo Moro, 70010 Valenzano, BA, ItalyDepartment of Pharmacology, Faculty of Veterinary Medicine, University of Murcia, 30100 Murcia, SpainA single-dose disposition kinetics for tildipirosin was evaluated in clinically healthy ewes (<i>n</i> = 6) after intravenous (IV), intramuscular (IM), and subcutaneous (SC) administration of a commercial formulation. Tildipirosin concentrations were determined by high-performance liquid chromatography with ultraviolet detection. Plasma concentration-time data was calculated by non-compartmental pharmacokinetic methods. The apparent volume of distribution (Vz) of tildipirosin after IV administration was 5.36 ± 0.57 L/kg suggesting a wide distribution in tissues and inside the cells. The elimination half-life (t½λz) was 17.16 ± 2.25, 23.90 ± 6.99 and 43.19 ± 5.17 h after IV, IM and SC administration, respectively. Following IM administration, tildipirosin was rapidly absorbed (tmax = 0.62 ± 0.10 h) even to a greater extent than after SC administration. Time to reach peak concentration (tmax) and peak plasma concentrations (Cmax) differed significantly, but both parameters showed a more significant variability after SC than after IM administration. Bioavailabilities after extravascular administration were high (>70%). Therefore, given general adverse reactions that were not observed in any ewe and favourable pharmacokinetics, tildipirosin could be effective in treating bacterial infections in sheep.https://www.mdpi.com/2076-2615/10/8/1332macrolidespharmacokineticssheepewestildipirosin |
| spellingShingle | Juan Sebastián Galecio Elisa Escudero José Joaquín Cerón Giuseppe Crescenzo Pedro Marín Pharmacokinetics of Tildipirosin in Ewes after Intravenous, Intramuscular and Subcutaneous Administration Animals macrolides pharmacokinetics sheep ewes tildipirosin |
| title | Pharmacokinetics of Tildipirosin in Ewes after Intravenous, Intramuscular and Subcutaneous Administration |
| title_full | Pharmacokinetics of Tildipirosin in Ewes after Intravenous, Intramuscular and Subcutaneous Administration |
| title_fullStr | Pharmacokinetics of Tildipirosin in Ewes after Intravenous, Intramuscular and Subcutaneous Administration |
| title_full_unstemmed | Pharmacokinetics of Tildipirosin in Ewes after Intravenous, Intramuscular and Subcutaneous Administration |
| title_short | Pharmacokinetics of Tildipirosin in Ewes after Intravenous, Intramuscular and Subcutaneous Administration |
| title_sort | pharmacokinetics of tildipirosin in ewes after intravenous intramuscular and subcutaneous administration |
| topic | macrolides pharmacokinetics sheep ewes tildipirosin |
| url | https://www.mdpi.com/2076-2615/10/8/1332 |
| work_keys_str_mv | AT juansebastiangalecio pharmacokineticsoftildipirosininewesafterintravenousintramuscularandsubcutaneousadministration AT elisaescudero pharmacokineticsoftildipirosininewesafterintravenousintramuscularandsubcutaneousadministration AT josejoaquinceron pharmacokineticsoftildipirosininewesafterintravenousintramuscularandsubcutaneousadministration AT giuseppecrescenzo pharmacokineticsoftildipirosininewesafterintravenousintramuscularandsubcutaneousadministration AT pedromarin pharmacokineticsoftildipirosininewesafterintravenousintramuscularandsubcutaneousadministration |